The Foundations of Orphan Drugs Webinar series
Name: Jim Geraghty
Webinar: Funding Orphan Drugs
Title: Entrepreneur in residence
Company: Third Rock Ventures
Jim Geraghty joined Third Rock Ventures in 2013 with a desire to create companies dedicated to improving the lives of patients with rare genetic diseases. With over 30 years of strategic and leadership experience at the top of the orphan drug industry, including more than 20 years developing and commercializing therapies for rare diseases, Jim has played a crucial role in the creation and financing of Cambridge based Voyager Therapeutics. Voyager Therapeutics is dedicated to creating treatments for CNS diseases using a adeno-associated vectors, and earlier this year secured $45 million in a series A financing round.
Prior to Third Rock, Jim served as senior vice president, North America strategy and business development at Sanofi. Before Sanofi, Jim spent 20 years at Genzyme, where his roles included senior vice president international development, president of Genzyme Europe and general manager of Genzyme’s cardiovascular business. He also served as chairman and chief executive officer of GTC Biotherapeutics (formerly Genzyme Transgenics), which he founded and took public. Jim oversaw Genzyme’s Humanitarian Assistance for Neglected Diseases program, under which the company supported innovative therapeutic programs on a non-commercial basis. He is chairman of Idera Pharmaceuticals, a member of the Joslin Diabetes Center board of trustees and serves on the board of BIO Ventures for Global Health. A graduate of the Yale Law School, Jim also holds a masters degree from the University of Pennsylvania and a bachelors from Georgetown University.